138 related articles for article (PubMed ID: 21325450)
1. RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer.
Knappskog S; Myklebust LM; Busch C; Aloysius T; Varhaug JE; Lønning PE; Lillehaug JR; Pendino F
Ann Oncol; 2011 Oct; 22(10):2208-15. PubMed ID: 21325450
[TBL] [Abstract][Full Text] [Related]
2. CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia.
Astori A; Fredly H; Aloysius TA; Bullinger L; Mansat-De Mas V; de la Grange P; Delhommeau F; Hagen KM; Récher C; Dusanter-Fourt I; Knappskog S; Lillehaug JR; Pendino F; Bruserud Ø
Oncotarget; 2013 Sep; 4(9):1438-48. PubMed ID: 23988457
[TBL] [Abstract][Full Text] [Related]
3. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the novel tumor-suppressor gene CCDC67 in papillary thyroid carcinoma.
Yin DT; Xu J; Lei M; Li H; Wang Y; Liu Z; Zhou Y; Xing M
Oncotarget; 2016 Feb; 7(5):5830-41. PubMed ID: 26716505
[TBL] [Abstract][Full Text] [Related]
5. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.
Thor AD; Moore DH II; Edgerton SM; Kawasaki ES; Reihsaus E; Lynch HT; Marcus JN; Schwartz L; Chen LC; Mayall BH
J Natl Cancer Inst; 1992 Jun; 84(11):845-55. PubMed ID: 1317462
[TBL] [Abstract][Full Text] [Related]
6. The epigenetic regulator RINF (CXXC5) maintains
Astori A; Matherat G; Munoz I; Gautier EF; Surdez D; Zermati Y; Verdier F; Zaidi S; Feuillet V; Kadi A; Lauret E; Delattre O; Lefèvre C; Fontenay M; Ségal-Bendirdjian E; Dusanter-Fourt I; Bouscary D; Hermine O; Mayeux P; Pendino F
Haematologica; 2022 Jan; 107(1):268-283. PubMed ID: 33241676
[TBL] [Abstract][Full Text] [Related]
7. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
8. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.
Lukas J; Gao DQ; Keshmeshian M; Wen WH; Tsao-Wei D; Rosenberg S; Press MF
Cancer Res; 2001 Apr; 61(7):3212-9. PubMed ID: 11306511
[TBL] [Abstract][Full Text] [Related]
9. Mutation and expression of TP53 in malignant melanomas.
Weiss J; Heine M; Arden KC; Körner B; Pilch H; Herbst RA; Jung EG
Recent Results Cancer Res; 1995; 139():137-54. PubMed ID: 7597286
[TBL] [Abstract][Full Text] [Related]
10. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
11. The combined use of miRNAs and mRNAs as biomarkers for the diagnosis of papillary thyroid carcinoma.
Zhao Y; Liu X; Zhong L; He M; Chen S; Wang T; Ma S
Int J Mol Med; 2015 Oct; 36(4):1097-103. PubMed ID: 26252081
[TBL] [Abstract][Full Text] [Related]
12. Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target.
Magro G; Cataldo I; Amico P; Torrisi A; Vecchio GM; Parenti R; Asioli S; Recupero D; D'Agata V; Mucignat MT; Perris R
Thyroid; 2011 Mar; 21(3):267-77. PubMed ID: 21323588
[TBL] [Abstract][Full Text] [Related]
13. Functional involvement of RINF, retinoid-inducible nuclear factor (CXXC5), in normal and tumoral human myelopoiesis.
Pendino F; Nguyen E; Jonassen I; Dysvik B; Azouz A; Lanotte M; Ségal-Bendirdjian E; Lillehaug JR
Blood; 2009 Apr; 113(14):3172-81. PubMed ID: 19182210
[TBL] [Abstract][Full Text] [Related]
14. The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation.
Chernaya G; Mikhno N; Khabalova T; Svyatchenko S; Mostovich L; Shevchenko S; Gulyaeva L
Surg Oncol; 2018 Dec; 27(4):702-708. PubMed ID: 30449496
[TBL] [Abstract][Full Text] [Related]
15. FUCA1 is induced by wild-type p53 and expressed at different levels in thyroid cancers depending on p53 status.
Tsuchida N; Ikeda MA; Ιshino Υ; Grieco M; Vecchio G
Int J Oncol; 2017 Jun; 50(6):2043-2048. PubMed ID: 28440416
[TBL] [Abstract][Full Text] [Related]
16. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
[TBL] [Abstract][Full Text] [Related]
17. Differential Gene Expression of BRCA1,ERBB2 and TP53 biomarkers between Human Breast Tissue and Peripheral Blood Samples of Breast Cancer.
Zghair AN; Sinha DK; Kassim A; Alfaham M; Sharma AK
Anticancer Agents Med Chem; 2016; 16(4):519-25. PubMed ID: 26299666
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
[TBL] [Abstract][Full Text] [Related]
20. CHI3L1 overexpression is associated with metastasis and is an indicator of poor prognosis in papillary thyroid carcinoma.
Luo D; Chen H; Lu P; Li X; Long M; Peng X; Huang M; Huang K; Lin S; Tan L; Zhu Y; Chen Z; Ouyang N; Li H
Cancer Biomark; 2017; 18(3):273-284. PubMed ID: 28009325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
